Jun 14, 2023 / 08:20PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Welcome, everyone, to the afternoon start for the 44th Annual Goldman Sachs Healthcare Conference. My name is Chris Shibutani, member of the Biopharma Equity Research team. We are very pleased to have Nektar Therapeutics join us once again. On the dice with me are some veterans of the industry, of the company. Jonathan Zalevsky, also known as JZ, Chief Research and Development Officer; and Jen Ruddock, Chief Business Officer.
Thank you both for joining us.
Jonathan Zalevsky - Nektar Therapeutics - Senior VP & Chief Research and Development Officer
Thank you.
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
You guys have been really a part of so many aspects of the journey for the company. We're at an interesting intersection right now. A lot of changes going over the past 6 months, and probably changes that are not necessarily understood or recognized or appreciated as much. And I always
Nektar Therapeutics at Goldman Sachs Healthcare Conference Transcript
Mar 05, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers